Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen

Journal of the National Cancer Institute

Volumn 96, Issue 23, 2004, Pages 1762-1769

  McCaskill Stevens, Worta ^a   Wilson, John ^b   Bryant, John ^b   Mamounas, Eleftherios ^c   Garvey, Lori ^d   James, Joan ^e   Cronin, Walter ^b   Wickerham, D Lawrence ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c AULTMAN HOSPITAL   (United States)

^d National Surgical Adjuvant Breast   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; METHOTREXATE; TAMOXIFEN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CANCER; CALCULATION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL ANALYSIS; THROMBOEMBOLISM;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; THROMBOEMBOLISM;

EID: 10644286507     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh321     Document Type: Article

References (44)

1. Chen Y, Thompson W, Semenciw R, Mao, Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarker Prev 1999;8:855-61.
2. Hislop T, Elwood J, Coldman, AJ, Spinelli, JJ, Worth AJ, Ellison LG. Second primary cancers of the breast: incidence and risk factors. Br J Cancer 1984;49:79-85.
3. Bernstein J, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 1992;136:925-36.
4. Broet P, Rochefordiere A, Scholl S, Fourquet A, Mosseriv, Durand J, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578-83.
5. Adami H, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based control study. Cancer 1985;55:643-7.
6. Hankey BF, Curtis RE, Naughton MD, Boice JD, Flannery JT. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J Natl Cancer Inst 1983;70:797-804.
7. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. J Natl Cancer Inst Monogr 1985;68:99-103.
8. Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 2003;89:513-8.
9. Dignam JL, Wieand K, Johnson KA., Fisher B, Xu L, Mamounas E. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003;95:1467-74
10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451-67.
11. Fisher B, Dignam J, Bryant J, DeCillis AD, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
12. Cook L, Weiss N, Schwartz S, White E, McKnight B, Moore DE, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87:1359-64.
13. Fisher B, Costantino JP, Wickerham L, Redmond C, Kavanah M, Cronin W, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88
14. Powles T. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:90-101.
15. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from breast cancer with tamoxifen trial among hysterectomised women. Lancet 1998;352:93-7.
16. IBIS Investigators. First results of the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002;360: 817-24.
17. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast cancer prevention. Lancet 2003; 361:296-300.
18. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sascchini V, Travaglini R, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.
19. Nevassari K, Heikkinein U, Taslonen PJ. Tamoxifen and thrombosis. Lancet 1978;2:946-7.
20. Henderick A, Sebrammanian VP. Tamoxifen and thromboembolism. JAMA 1980;243:514-5.
21. Swain M, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-23.
22. Mamounas ER, Bryant J, Fisher B, Wickerham DL, Wolmark N. Primary breast cancer as a risk factor of subsequent contralateral breast cancer; NSABP experience from 9 randomized trials. 21st Annual San Antonio Breast Cancer Symposium; 1998. Breast Cancer Res Treat 1998;50:230.
23. McCaskill-Stevens W, Bryant J, Costantino J, Wickerham DL, Vogel V, Wolmark N. Incidence of contralateral breast cancer (cbc), endometrial cancer (ec) thromboembolic events (te) in African American women receiving tamoxifen for treatment of primary breast cancer [abstract 269]. Proc ASCO 2000;70a.
24. Arriagada R, Rutqvist LE. Adjuvant chemotherapy in early breast cancer and incidence or new primary malignancies. Lancet 1991;338:535-8.
25. Dignam J, Redmond CK, Fisher B, Costantino JP, Edwards BK. Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from 2 randomized clinical trials of the NSABP. Cancer 1997;80:80-90.
26. Roach M 3rd, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, et al. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am 1997;3:107-12.
27. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiation Oncol Biol Phys 2003;56:1038-45.
28. Flaws JA, Bush TL. Racial differences in drug metabolism: an explanation for higher breast cancer mortality in blacks? Med Hypotheses 1998;50: 327-9.
29. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-306.
30. Anderson WF, Chu KC, Chang S, Sherman M. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:1128-35.
31. Klonoff-Cohen HS, Schaffroth LB, Edelstein SL, Molgaard C, Saltzstein SL. Breast cancer histology in Caucasians, African Americans, Hispanics, Asians, and Pacific Islanders. Ethnic Health 1998;3:189-98.
32. Cook LS, White E, Schwartz SM, Weiss NS. A population-based study of contralateral breast cancer following a first primary breast cancer. Cancer Causes Control 1996;7:382-90.
33. Forshee RA, Storey ML, Ritenbaugh C. Breast cancer risk and lifestyle differences among premenopausal and postmenopausal African-American women and white women. Cancer 2003;97(1 Suppl):280-8.
34. Hall IJ, Newman B, Millikan RC, Moorman PG. Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 2000;151:754-64.
35. Chen VW, Correa P, Jurman R, Wu XC, Eley W. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-35.
36. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
37. Altuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast cancer among very young premenopausal women (U.S.). Cancer Causes Control 2003;2:151-60.
38. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588-93.
39. Eisen A. A meta-analysis of randomized trials of tamoxifen for the prevention of breast cancer [abstract 391]. Proc ASCO 2003;98.
40. Dowling NF, Austin H, Dilly A, Whitesell E, BL, Hooper, WC. The epidemiology of venous thrombosis in Caucasian and African American: the GATE study. J Thromb Haemostatis 2003;1:80-7.
41. Gail M, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
42. Claus E, Stowe M, Carter D, Holford T. The risk of contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. The Breast 2003;12: 451-6.
43. Sullivan V, Denk PM, Sonnad SS, Eagleton MJ, Wakefield TW. Ligation versus anticoagulation: treatment of above-knee superficial thrombophlebitis not involving the deep venous system. Am Coll Surg 2000;193:556-62.
44. Ascer E, Lorensen E, Pollina RM, Gennaro M. Preliminary results of a nonoperative approach to saphenofemoral junction thrombophlebitis. J Vasc Surg 1995;22:616-21.